Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Moderna’s Shift to Cancer Company Lifts Stock Up 177%

The New York Times – Business:

The company’s fortunes cratered as demand for Covid-19 vaccines plummeted. But it was busy working on something else.

Rebecca Robbins
Author: Rebecca Robbins

This post first appeared in The New York Times – Business. Read the original article.

Written by

Rebecca Robbins

in

Bancel, Stephane, Coronavirus (2019-nCoV), Drugs (Pharmaceuticals), Health and Human Services Department, Kennedy, Robert F Jr, Merck & Company Inc, Moderna Inc, Trump, Donald J, Vaccination and Immunization
←Can We Do Anything About Tick-Borne Diseases Like Alpha-Gal Syndrome?
How Usher Gets Ready for a Show→

More posts

  • ‘Could be a crime’: Todd Blanche doubles down on Alaska lawsuit

  • Serbia’s Vučić concedes election defeat to student-led protest movement

  • End approaching for Carrick but Man Utd owners’ problems far bigger

  • Amanda Seyfried Explains Turning Down ‘Guardians of the Galaxy’ For Family: “Just Not For Me”

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube